Amplyx Pharmaceuticals modifies existing small molecule drugs to create more targeted, less toxic therapeutics. Amplyx is developing novel anti-infective drugs to treat invasive fungal infections and HIV. Their advantage is based on innovative chemistry to modify challenging drug targets, as well as licensed intellectual property from Stanford University to protect their methods to improve existing drugs.